{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T21:13:32Z","timestamp":1723151612999},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Protein Cell"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s13238-010-0139-2","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T03:20:43Z","timestamp":1294370443000},"page":"1084-1092","source":"Crossref","is-referenced-by-count":3,"title":["Influence of glycosylation and oligomerization of vaccinia virus complement control protein on level and pattern of functional activity and immunogenicity"],"prefix":"10.1093","volume":"1","author":[{"given":"Girish J.","family":"Kotwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,1,8]]},"reference":[{"key":"139_CR1","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1099\/vir.0.008474-0","volume":"90","author":"J.E. Adamo","year":"2009","unstructured":"Adamo, J.E., Meseda, C.A., Weir, J.P., and Merchlinsky, M.J. (2009). Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein. J Gen Virol 90, 2604\u20132608.","journal-title":"J Gen Virol"},{"key":"139_CR2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/00007890-200103270-00019","volume":"71","author":"F. Al-Mohanna","year":"2001","unstructured":"Al-Mohanna, F., Parhar, R., and Kotwal, G.J. (2001). Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation 71, 796\u2013801.","journal-title":"Transplantation"},{"key":"139_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0966-3274(02)00149-1","volume":"11","author":"J.B. Anderson","year":"2003","unstructured":"Anderson, J.B., Smith, S.A., van Wijk, R., Chien, S., and Kotwal, G.J. (2003). Vaccinia virus complement control protein inhibits hyperacute xenorejection in a guinea pig-to-rat heterotopic cervical cardiac xenograft model by blocking both xenoantibody binding and complement pathway activation. Transpl Immunol 11, 129\u2013135.","journal-title":"Transpl Immunol"},{"key":"139_CR4","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1128\/JVI.70.9.6418-6424.1996","volume":"70","author":"B.S. Bender","year":"1996","unstructured":"Bender, B.S., Rowe, C.A., Taylor, S.F., Wyatt, L.S., Moss, B., and Small, P.A. Jr. (1996). Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 70, 6418\u20136424.","journal-title":"J Virol"},{"key":"139_CR5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/313812","volume":"30","author":"T.J. Cieslak","year":"2000","unstructured":"Cieslak, T.J., Christopher, G.W., Kortepeter, M.G., Rowe, J.R., Pavlin, J.A., Culpepper, R.C., and Eitzen, E.M. Jr. (2000). Immunization against potential biological warfare agents. Clin Infect Dis 30, 843\u2013850.","journal-title":"Clin Infect Dis"},{"key":"139_CR6","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1128\/JVI.02098-06","volume":"81","author":"W. Dowling","year":"2007","unstructured":"Dowling, W., Thompson, E., Badger, C., Mellquist, J.L., Garrison, A. R., Smith, J.M., Paragas, J., Hogan, R.J., and Schmaljohn, C. (2007). Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol 81, 1821\u20131837.","journal-title":"J Virol"},{"key":"139_CR7","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.vaccine.2005.03.029","volume":"24","author":"C. Empig","year":"2006","unstructured":"Empig, C., Kenner, J.R., Perret-Gentil, M., Youree, B.E., Bell, E., Chen, A., Gurwith, M., Higgins, K., Lock, M., Rice, A.D., et al. (2006). Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 24, 3686\u20133694.","journal-title":"Vaccine"},{"key":"139_CR8","volume-title":"Smallpox and its eradication","author":"F. Fenner","year":"1988","unstructured":"Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. (1988) Smallpox and its eradication. Geneva: World Health Organization"},{"key":"139_CR9","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1073\/pnas.0400744101","volume":"101","author":"V.K. Ganesh","year":"2004","unstructured":"Ganesh, V.K., Smith, S.A., Kotwal, G.J., and Murthy, K.H.M. (2004). Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation. Proc Natl Acad Sci USA 101, 8924\u20138929.","journal-title":"Proc Natl Acad Sci USA"},{"key":"139_CR10","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1099\/vir.0.82708-0","volume":"88","author":"A. Garcel","year":"2007","unstructured":"Garcel, A., Crance, J.-M., Drillien, R., Garin, D., and Favier, A.-L. (2007). Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses. J Gen Virol 88, 1906\u20131916","journal-title":"J Gen Virol"},{"key":"139_CR11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.vaccine.2008.11.063","volume":"27","author":"A. Garcel","year":"2009","unstructured":"Garcel, A., Perino, J., Crance, J.M., Drillien, R., Garin, D., and Favier, A.L. (2009). Phenotypic and genetic diversity of the traditional Lister smallpox vaccine. Vaccine 27, 708\u2013717.","journal-title":"Vaccine"},{"key":"139_CR12","unstructured":"Ghebremariam, Y.T. (2006). Ph. D. thesis. University of Cape Town, South Africa"},{"key":"139_CR13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1196\/annals.1352.024","volume":"1056","author":"Y.T. Ghebremariam","year":"2005","unstructured":"Ghebremariam, Y.T., Odunuga, O.O., Janse, K., and Kotwal, G.J. (2005). Humanized recombinant vaccinia virus complement control protein (hrVCP) with three amino acid changes, H98Y, E102K, and E120K creating an additional putative heparin binding site, is 100-fold more active than rVCP in blocking both classical and alternative complement pathways. Ann N Y Acad Sci 1056, 113\u2013122.","journal-title":"Ann N Y Acad Sci"},{"key":"139_CR14","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","volume":"281","author":"D.A. Henderson","year":"1999","unstructured":"Henderson, D.A., Inglesby, T.V., Bartlett, J.G., Ascher, M.S, Eitzen, E., Jahrling, P.B., et al (1999). Smallpox as a Biological Weapon. JAMA 281, 2127\u20132137.","journal-title":"JAMA"},{"key":"139_CR15","doi-asserted-by":"crossref","first-page":"13411","DOI":"10.1016\/S0021-9258(18)77358-4","volume":"265","author":"A. Ichinose","year":"1990","unstructured":"Ichinose, A., Bottenus, R.E., and Davie, E.W. (1990). Structure of transglutaminases. J Biol Chem 265, 13411\u201313414.","journal-title":"J Biol Chem"},{"key":"139_CR16","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1128\/JVI.77.15.8256-8262.2003","volume":"77","author":"S.N. Isaacs","year":"2003","unstructured":"Isaacs, S.N., Argyropoulos, E., Sfyroera, G., Mohammad, S., and Lambris, J.D. (2003). Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J Virol 77, 8256\u20138262.","journal-title":"J Virol"},{"key":"139_CR17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1196\/annals.1352.004","volume":"1056","author":"P. Jha","year":"2005","unstructured":"Jha, P., Smith, S.A., Justus, D.E., and Kotwal, G.J. (2005). Vaccinia virus complement control protein ameliorates collagen-induced arthritic mice. Ann N Y Acad Sci 1056, 55\u201368.","journal-title":"Ann N Y Acad Sci"},{"key":"139_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0042-6822(62)90172-1","volume":"18","author":"W.K. Joklik","year":"1962","unstructured":"Joklik, W.K. (1962). The purification fo four strains of poxvirus. Virology 18, 9\u201318.","journal-title":"Virology"},{"key":"139_CR19","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0041-1345(03)00485-8","volume":"35","author":"D. Kahn","year":"2003","unstructured":"Kahn, D., Smith, S.A., and Kotwal, G.J. (2003). Dose-dependent inhibition of complement in baboons by vaccinia virus complement control protein: implications in xenotransplantation. Transplant Proc 35, 1606\u20131608.","journal-title":"Transplant Proc"},{"key":"139_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-4419-0901-5_8","volume":"653","author":"Y.H. Kang","year":"2009","unstructured":"Kang, Y.H., Tan, L.A., Carroll, M.V., Gentle, M.E., and Sim, R.B. (2009). Target pattern recognition by complement proteins of the classical and alternative pathways. Adv Exp Med Biol 653, 117\u2013128.","journal-title":"Adv Exp Med Biol"},{"key":"139_CR21","first-page":"76","volume":"12","author":"G.J. Kotwal","year":"1994","unstructured":"Kotwal, G.J. (1994). Purification of virokines using ultrafiltration. Am Biotechnol Lab 12, 76\u201377.","journal-title":"Am Biotechnol Lab"},{"key":"139_CR22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0167-5699(00)01606-6","volume":"21","author":"G.J. Kotwal","year":"2000","unstructured":"Kotwal, G.J. (2000). Poxviral mimicry of complement and chemokine system components: what\u2019s the end game? Immunol Today 21, 242\u2013248.","journal-title":"Immunol Today"},{"key":"139_CR23","first-page":"101","volume":"269","author":"G.J. Kotwal","year":"2004","unstructured":"Kotwal, G.J., and Abrahams, M.R. (2004). Growing poxviruses and determining virus titer. Methods Mol Biol 269, 101\u2013112.","journal-title":"Methods Mol Biol"},{"key":"139_CR24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.2237434","volume":"250","author":"G.J. Kotwal","year":"1990","unstructured":"Kotwal, G.J., Isaacs, S.N., McKenzie, R., Frank, M.M., and Moss, B. (1990). Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250, 827\u2013830.","journal-title":"Science"},{"key":"139_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1006844624825","volume":"185","author":"G.J. Kotwal","year":"1998","unstructured":"Kotwal, G.J., Miller, C.G., and Justus, D.E. (1998a). The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation. Mol Cell Biochem 185, 39\u201346.","journal-title":"Mol Cell Biochem"},{"key":"139_CR26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/335176a0","volume":"335","author":"G.J. Kotwal","year":"1988","unstructured":"Kotwal, G.J., and Moss, B. (1988). Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335, 176\u2013178.","journal-title":"Nature"},{"key":"139_CR27","unstructured":"Kotwal, G.J., Reynolds, D., Keeling, K., Howard, J., and Justus, D.E. (1998b) Vaccinia virus complement control protein is a virokine with lysozyme-like heparin-binding activity: possible implications in prolonged evasion of host immune response. In: Proceedings of the 10th International Congress of Immunology. Talwar, G. P., Nath, I., Ganguly, N. K., and Rao, K. V. S. (ed.), New Delhi, 315\u2013320."},{"key":"139_CR28","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.156.11.4415","volume":"156","author":"M.K. Liszewski","year":"1996","unstructured":"Liszewski, M.K., and Atkinson, J.P. (1996). Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement. J Immunol 156, 4415\u20134421.","journal-title":"J Immunol"},{"key":"139_CR29","doi-asserted-by":"crossref","first-page":"37692","DOI":"10.1074\/jbc.M004650200","volume":"275","author":"M.K. Liszewski","year":"2000","unstructured":"Liszewski, M.K., Leung, M., Cui, W., Subramanian, V.B., Parkinson, J., Barlow, P.N., Manchester, M., and Atkinson, J.P. (2000). Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem 275, 37692\u201337701.","journal-title":"J Biol Chem"},{"key":"139_CR30","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.4049\/jimmunol.161.7.3711","volume":"161","author":"M.K. Liszewski","year":"1998","unstructured":"Liszewski, M.K., Leung, M.K., and Atkinson, J.P. (1998). Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function. J Immunol 161, 3711\u20133718.","journal-title":"J Immunol"},{"key":"139_CR31","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.4049\/jimmunol.176.6.3725","volume":"176","author":"M.K. Liszewski","year":"2006","unstructured":"Liszewski, M.K., Leung, M.K., Hauhart, R., Buller, R.M., Bertram, P., Wang, X., Rosengard, A.M., Kotwal, G.J., and Atkinson, J.P. (2006). Structure and regulatory profile of the monkey-pox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol 176, 3725\u20133734.","journal-title":"J Immunol"},{"key":"139_CR32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/infdis\/166.6.1245","volume":"166","author":"R. McKenzie","year":"1992","unstructured":"McKenzie, R., Kotwal, G.J., Moss, B., Hammer, C.H., and Frank, M. M. (1992). Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis 166, 1245\u20131250.","journal-title":"J Infect Dis"},{"key":"139_CR33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1006\/cimm.1995.1086","volume":"162","author":"C.G. Miller","year":"1995","unstructured":"Miller, C.G., Justus, D.E., Jayaraman, S., and Kotwal, G.J. (1995). Severe and prolonged inflammatory response to localized cowpox virus infection in footpads of C5-deficient mice: investigation of the role of host complement in poxvirus pathogenesis. Cell Immunol 162, 326\u2013332.","journal-title":"Cell Immunol"},{"key":"139_CR34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/viro.1996.8396","volume":"33","author":"C.G. Miller","year":"1997","unstructured":"Miller, C.G., Shchelkunov, S.N., and Kotwal, G.J. (1997). The cowpox virus encoded homolog of vaccinia virus is an inflammation modulatory protein. Virology 33, 126\u2013133.","journal-title":"Virology"},{"key":"139_CR35","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","volume":"79","author":"S. Morikawa","year":"2005","unstructured":"Morikawa, S., Sakiyama, T., Hasegawa, H., Saijo, M., Maeda, A., Kurane, I., Maeno, G., Kimura, J., Hirama, C., Yoshida, T., et al. (2005). An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. J Virol 79, 11873\u201311891.","journal-title":"J Virol"},{"key":"139_CR36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/j.1460-2075.1984.tb01776.x","volume":"3","author":"B.J. Morley","year":"1984","unstructured":"Morley, B.J., Campbell, R.D. (1984). Internal homologies of the Ba fragment from human complement component Factor B, a class III MHC antigen. EMBO J 3,153\u2013157.","journal-title":"EMBO J"},{"key":"139_CR37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0092-8674(01)00214-8","volume":"104","author":"K.H.M. Murthy","year":"2001","unstructured":"Murthy, K.H.M., Smith, S.A., Ganesh, V.K., Judge, K.W., Mullin, N., Barlow, P.N., Ogata, C.M., and Kotwal, G.J. (2001). Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104, 301\u2013311.","journal-title":"Cell"},{"key":"139_CR38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0022-2836(91)90666-T","volume":"219","author":"D.G. Norman","year":"1991","unstructured":"Norman, D.G., Barlow, P.N., Baron, M., Day, A.J., Sim, R.B., Campbell, I.D.(1991). Three-dimensional structure of a complement control protein module in solution. J Mol Biol 219, 717\u2013725.","journal-title":"J Mol Biol"},{"key":"139_CR39","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1128\/JVI.76.15.7713-7723.2002","volume":"76","author":"B.T. Ober","year":"2002","unstructured":"Ober, B.T., Br\u00fchl, P., Schmidt, M., Wieser, V., Gritschenberger, W., Coulibaly, S., Savidis-Dacho, H., Gerencer, M., and Falkner, F.G. (2002). Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol 76, 7713\u20137723.","journal-title":"J Virol"},{"issue":"Supplement1","key":"139_CR40","first-page":"15","volume":"272","author":"O.O. Odunuga","year":"2005","unstructured":"Odunuga, O.O., Ghebremariam, Y.T., and Kotwal, G.J. (2005). Lister homologue of vaccinia virus complement control protein is two amino acids shorter, has putative glycosylation sites and other functional and structural differences. FEBS J 272(Supplement 1), 15\u201316.","journal-title":"FEBS J"},{"key":"139_CR41","first-page":"237","volume-title":"Advances in Animal Virology","author":"D.N. Reynolds","year":"2000","unstructured":"Reynolds, D.N., Keeling, K.L., Molestina, R., Srisatjaluk, R., Butterfield, J.H., Ehringer, W., et al. (2000) Heparin binding activity of vaccinia virus complement control protein confers additional properties of uptake by mast cells and attachment to endothelial cells. In: Advances in Animal Virology, Jameel, S., and Lambris, J. D., ed. New York: Oxford & IBH, 237\u2013342."},{"key":"139_CR42","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1073\/pnas.112220499","volume":"99","author":"A.M. Rosengard","year":"2002","unstructured":"Rosengard, A.M., Liu, Y., Nie, Z., and Jimenez, R. (2002). Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci U S A 99, 8808\u20138813.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"139_CR43","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3201\/eid0706.010602","volume":"7","author":"S.R. Rosenthal","year":"2001","unstructured":"Rosenthal, S.R., Merchlinsky, M., Kleppinger, C., and Goldenthal, K. L. (2001). Developing new smallpox vaccines. Emerg Infect Dis 7, 920\u2013926.","journal-title":"Emerg Infect Dis"},{"key":"139_CR44","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.4049\/jimmunol.160.11.5596","volume":"160","author":"A. Sahu","year":"1998","unstructured":"Sahu, A., Isaacs, S.N., Soulika, A.M., and Lambris, J.D. (1998). Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immunol 160, 5596\u20135604.","journal-title":"J Immunol"},{"key":"139_CR45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/109629603322761373","volume":"4","author":"M.J. Scott","year":"2003","unstructured":"Scott, M.J., Burch, P.T., Jha, P., Peyton, J.C., Kotwal, G.J., and Cheadle, W.G. (2003). Vaccinia virus complement control protein increases early bacterial clearance during experimental peritonitis. Surg Infect (Larchmt) 4, 317\u2013326.","journal-title":"Surg Infect (Larchmt)"},{"key":"139_CR46","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4049\/jimmunol.174.4.2143","volume":"174","author":"G. Sfyroera","year":"2005","unstructured":"Sfyroera, G., Katragadda, M., Morikis, D., Isaacs, S.N., and Lambris, J.D. (2005). Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol 174, 2143\u20132151.","journal-title":"J Immunol"},{"key":"139_CR47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/14712598.1.3.343","volume":"1","author":"S.A. Smith","year":"2001","unstructured":"Smith, S.A., and Kotwal, G.J. (2001). Virokines: novel immunomodulatory agents. Expert Opin Biol Ther 1, 343\u2013357.","journal-title":"Expert Opin Biol Ther"},{"key":"139_CR48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0167-4838(02)00339-4","volume":"1598","author":"S.A. Smith","year":"2002","unstructured":"Smith, S.A., Krishnasamy, G., Murthy, K.H.M., Cooper, A., Bromek, K., Barlow, P.N., and Kotwal, G.J. (2002). Vaccinia virus complement control protein is monomeric, and retains structural and functional integrity after exposure to adverse conditions. Biochim Biophys Acta 1598, 55\u201364.","journal-title":"Biochim Biophys Acta"},{"key":"139_CR49","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1128\/JVI.74.12.5659-5666.2000","volume":"74","author":"S.A. Smith","year":"2000","unstructured":"Smith, S.A., Mullin, N.P., Parkinson, J., Shchelkunov, S.N., Totmenin, A.V., Loparev, V.N., Srisatjaluk, R., Reynolds, D.N., Keeling, K.L., Justus, D.E., et al. (2000). Conserved surface-exposed K\/R-X-K\/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense. J Virol 74, 5659\u20135666.","journal-title":"J Virol"},{"key":"139_CR50","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1099\/0022-1317-79-7-1637","volume":"79","author":"L.M. Stannard","year":"1998","unstructured":"Stannard, L.M., Marais, D., Kow, D., and Dumbell, K.R. (1998). Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin. J Gen Virol 79, 1637\u20131646.","journal-title":"J Gen Virol"},{"key":"139_CR51","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","volume":"22","author":"J.D. Thompson","year":"1994","unstructured":"Thompson, J.D., Higgins, D.G., and Gibson, T.J. (1994). CLUSTALW: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22, 4673\u20134680.","journal-title":"Nucleic Acids Res"},{"key":"139_CR52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijid.2005.12.001","volume":"10","author":"R. Wittek","year":"2006","unstructured":"Wittek, R. (2006). Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis 10, 193\u2013201.","journal-title":"Int J Infect Dis"}],"container-title":["Protein & Cell"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13238-010-0139-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13238-010-0139-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13238-010-0139-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T19:32:02Z","timestamp":1685907122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/proteincell\/article\/1\/12\/1084\/6874081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1007\/s13238-010-0139-2","relation":{},"ISSN":["1674-800X","1674-8018"],"issn-type":[{"value":"1674-800X","type":"print"},{"value":"1674-8018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}